Integral Diagnostics Beheer
Beheer criteriumcontroles 2/4
De CEO Integral Diagnostics is Ian Kadish, benoemd in May2017, heeft een ambtstermijn van 7.5 jaar. De totale jaarlijkse vergoeding van { bedraagt A$ 1.24M, bestaande uit 66.3% salaris en 33.7% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.25% van de aandelen van het bedrijf, ter waarde A$ 1.73M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3 jaar en 1.8 jaar.
Belangrijke informatie
Ian Kadish
Algemeen directeur
AU$1.2m
Totale compensatie
Percentage CEO-salaris | 66.3% |
Dienstverband CEO | 7.5yrs |
Eigendom CEO | 0.3% |
Management gemiddelde ambtstermijn | 5yrs |
Gemiddelde ambtstermijn bestuur | 2.3yrs |
Recente managementupdates
Recent updates
Some Investors May Be Worried About Integral Diagnostics' (ASX:IDX) Returns On Capital
Feb 21Shareholders Will Probably Hold Off On Increasing Integral Diagnostics Limited's (ASX:IDX) CEO Compensation For The Time Being
Nov 22Integral Diagnostics' (ASX:IDX) Shareholders Will Receive A Smaller Dividend Than Last Year
Feb 20These 4 Measures Indicate That Integral Diagnostics (ASX:IDX) Is Using Debt Extensively
Dec 14Should You Think About Buying Integral Diagnostics Limited (ASX:IDX) Now?
May 26Integral Diagnostics (ASX:IDX) Is Paying Out Less In Dividends Than Last Year
Feb 28Integral Diagnostics Limited (ASX:IDX) Shares Could Be 38% Below Their Intrinsic Value Estimate
Feb 25Shareholders Would Not Be Objecting To Integral Diagnostics Limited's (ASX:IDX) CEO Compensation And Here's Why
Oct 29Does Integral Diagnostics (ASX:IDX) Deserve A Spot On Your Watchlist?
Sep 13An Intrinsic Calculation For Integral Diagnostics Limited (ASX:IDX) Suggests It's 22% Undervalued
Jun 04Should You Be Adding Integral Diagnostics (ASX:IDX) To Your Watchlist Today?
May 14Is Integral Diagnostics Limited (ASX:IDX) A Smart Choice For Dividend Investors?
May 03We Think Integral Diagnostics (ASX:IDX) Can Stay On Top Of Its Debt
Apr 16Is It Too Late To Consider Buying Integral Diagnostics Limited (ASX:IDX)?
Mar 27Is Integral Diagnostics Limited's (ASX:IDX) Stock's Recent Performance A Reflection Of Its Financial Health?
Mar 17The Trends At Integral Diagnostics (ASX:IDX) That You Should Know About
Mar 07Here's What We Like About Integral Diagnostics' (ASX:IDX) Upcoming Dividend
Feb 25Is Integral Diagnostics Limited (ASX:IDX) Popular Amongst Institutions?
Feb 23Have Insiders Been Selling Integral Diagnostics Limited (ASX:IDX) Shares?
Feb 13Integral Diagnostics Limited's (ASX:IDX) Intrinsic Value Is Potentially 46% Above Its Share Price
Feb 03Here's What We Learned About The CEO Pay At Integral Diagnostics Limited (ASX:IDX)
Jan 24Should You Use Integral Diagnostics's (ASX:IDX) Statutory Earnings To Analyse It?
Jan 14Shareholders Of Integral Diagnostics (ASX:IDX) Must Be Happy With Their 201% Total Return
Jan 05Is Integral Diagnostics (ASX:IDX) A Risky Investment?
Dec 26At AU$4.30, Is It Time To Put Integral Diagnostics Limited (ASX:IDX) On Your Watch List?
Dec 17What To Know Before Buying Integral Diagnostics Limited (ASX:IDX) For Its Dividend
Dec 08Returns On Capital At Integral Diagnostics (ASX:IDX) Paint An Interesting Picture
Nov 29Is Integral Diagnostics Limited's (ASX:IDX) Shareholder Ownership Skewed Towards Insiders?
Nov 19Is Integral Diagnostics (ASX:IDX) A Risky Investment?
Sep 20Analyse CEO-vergoeding
Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
---|---|---|---|
Jun 30 2024 | AU$1m | AU$825k | -AU$61m |
Mar 31 2024 | n/a | n/a | -AU$59m |
Dec 31 2023 | n/a | n/a | -AU$58m |
Sep 30 2023 | n/a | n/a | -AU$16m |
Jun 30 2023 | AU$1m | AU$794k | AU$25m |
Mar 31 2023 | n/a | n/a | AU$23m |
Dec 31 2022 | n/a | n/a | AU$21m |
Sep 30 2022 | n/a | n/a | AU$18m |
Jun 30 2022 | n/a | AU$781k | AU$15m |
Mar 31 2022 | n/a | n/a | AU$18m |
Dec 31 2021 | n/a | n/a | AU$22m |
Sep 30 2021 | n/a | n/a | AU$26m |
Jun 30 2021 | AU$2m | AU$736k | AU$31m |
Mar 31 2021 | n/a | n/a | AU$32m |
Dec 31 2020 | n/a | n/a | AU$32m |
Sep 30 2020 | n/a | n/a | AU$28m |
Jun 30 2020 | AU$1m | AU$635k | AU$23m |
Mar 31 2020 | n/a | n/a | AU$22m |
Dec 31 2019 | n/a | n/a | AU$21m |
Sep 30 2019 | n/a | n/a | AU$21m |
Jun 30 2019 | AU$876k | AU$549k | AU$21m |
Mar 31 2019 | n/a | n/a | AU$19m |
Dec 31 2018 | n/a | n/a | AU$17m |
Sep 30 2018 | n/a | n/a | AU$16m |
Jun 30 2018 | AU$711k | AU$489k | AU$15m |
Compensatie versus markt: De totale vergoeding ($USD 823.84K ) Ian } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de Australian markt ($USD 923.16K ).
Compensatie versus inkomsten: De vergoeding van Ian is gestegen terwijl het bedrijf verliesgevend is.
CEO
Ian Kadish (61 yo)
7.5yrs
Tenure
AU$1,243,752
Compensatie
Dr. Ian Kadish, MBBCh, MBA, has been the Chief Executive Officer, Managing Director and Director at Integral Diagnostics Limited since May 22, 2017. Dr. Kadish serves as Independent Non-Executive Director...
Leiderschapsteam
Naam | Positie | Tenure | Compensatie | Eigendom |
---|---|---|---|---|
CEO, MD & Director | 7.5yrs | AU$1.24m | 0.25% A$ 1.8m | |
Executive Director | 5yrs | AU$1.15m | 0.011% A$ 75.3k | |
Chief Financial Officer | less than a year | geen gegevens | geen gegevens | |
Chief Information Officer | 5.2yrs | geen gegevens | geen gegevens | |
Company Secretary | less than a year | geen gegevens | geen gegevens |
5.0yrs
Gemiddelde duur
Ervaren management: Het managementteam van IDX wordt beschouwd als ervaren (gemiddelde ambtstermijn 3 jaar).
Bestuursleden
Naam | Positie | Tenure | Compensatie | Eigendom |
---|---|---|---|---|
CEO, MD & Director | no data | AU$1.24m | 0.25% A$ 1.8m | |
Executive Director | 5yrs | AU$1.15m | 0.011% A$ 75.3k | |
Independent Non-Executive Director | 7.1yrs | AU$140.53k | 0.013% A$ 92.5k | |
Independent Non-Executive Director | 2.3yrs | AU$137.50k | 0.036% A$ 254.2k | |
Independent Non-Executive Director | 1.3yrs | AU$111.22k | 0.015% A$ 104.6k | |
Independent Non-Executive Chairman | 1.2yrs | AU$168.37k | 0.065% A$ 453.6k |
2.3yrs
Gemiddelde duur
59yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van IDX wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.8 jaar), wat duidt op een nieuw bestuur.